Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus

Veterinary Ophthalmology

Volumn 13, Issue 6, 2010, Pages 363-368

  Kador, Peter F ^a,b   Webb, Terah R ^c   Bras, Dineli ^c   Ketring, Kerry ^d   Wyman, Milton ^a,c,e  

^a Therapeutic Vision Inc   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MedVet Medical and Cancer Center for Pets   (United States)

^d All Animal Eye Clinic   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

Aldose reductase inhibitor; Cataracts; Diabetes mellitus; Dogs; Treatment

Indexed keywords

ALDEHYDE REDUCTASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOG; DOG DISEASE; DRUG ANTAGONISM; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ALDEHYDE REDUCTASE; ANIMALS; CATARACT; DIABETES COMPLICATIONS; DOG DISEASES; DOGS;

CANIS FAMILIARIS;

EID: 78349266468     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2010.00826.x     Document Type: Article

References (24)

1. Ionut V, Liu H, Mooradian V et al. Novel canine models of obese pre-diabetes and of mild type 2 diabetes. American Journal of Physiology, Endocrinology and Metabolism 2010; 298: 38-48.
2. Kim SP, Catalano KJ, Hsu IR et al. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. American Journal of Physiology, Endocrinology and Metabolism 2007; 292: E1590-E1598.
3. German AJ. The growing problem of obesity in dogs and cats. Journal of Nutrition 2006; 136: 1940S-1946S.
4. Klinkenberg H, Sallander MH, Hedhammar A. Feeding, exercise, and weight identified as risk factors in canine diabetes mellitus. Journal of Nutrition 2006;136:1985S-1987S.
5. Guptill L, Glickman L, Glickman N. Time trends and risk factors for diabetes mellitus in dogs: analysis of veterinary medical data base records (1970-1999). Veterinary Journal 2003; 165: 240-247.
6. Salgado D, Reusch C, Spiess B. Diabetic cataracts: different incidence between dogs and cats. Schweizer Archiv fur Tierheilkunde 2000; 142: 349-353.
7. Beam S, Correa MT, Davidson MG. A retrospective-cohort study on the development of cataracts in dogs with diabetes mellitus: 200 cases. Veterinary Ophthalmology 1999; 2: 169-172.
8. Basher AW, Roberts SM. Ocular manifestations of diabetes mellitus: diabetic cataracts in dogs. Veterinary Clinics of North America. Small Animal Practice 1995; 25: 661-676.
9. Richter M, Guscetti F, Spiess B. Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats. American Journal of Veterinary Research 2002; 63: 1591-1597.
10. Kinoshita JH. Mechanisms initiating cataract formation. Proctor Lecture. Investigative Ophthalmology 1974; 13: 713-724.
11. Kinoshita JH. Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture. American Journal of Ophthalmology 1986; 102: 685-692.
12. Kador PF, Kinoshita JH. Diabetic and galactosaemic cataracts. Ciba Foundation Symposium 1984; 106: 110-131.
13. Kador PF, Lee JW, Fujisawa S et al. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats. Journal of Ocular Pharmacology and Therapeutics 2000; 16: 149-160.
14. Ai Y, Zheng Z, O'Brien-Jenkins A et al. A mouse model of galactose-induced cataracts. Human Molecular Genetics 2000;9:1821-1827.
15. Lee AY, Chung SK, Chung SS. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 2780-2784.
16. Datiles 3rd MB, Fukui H. Cataract prevention in diabetic Octodon degus with Pfizer's sorbinil. Current Eye Research 1989; 8: 233-237.
17. Kador PF. Chapter 18: Ocular Pathology of Diabetes Mellitus. In: Doude's Foundations for Clinical Ophthalmology. (ed. Tasma WEAJ). Lippincott Williams & Wilkins, Philadelphia 2008; 84.
18. Hu TS, Datiles M, Kinoshita JH. Reversal of galactose cataract with Sorbinil in rats. Investigative Ophthalmology and Visual Science 1983; 24: 640-644.
19. Kador PF, Randazzo J, Babb T et al. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. Journal of Ocular Pharmacology and Therapeutics 2007; 23: 116-123.
20. Sato S, Mori K, Wyman M et al. Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Experimental Eye Research 1998; 66: 217-222.
21. Sato S, Takahashi Y, Wyman M et al. Progression of sugar cataract in the dog. Investigative Ophthalmology and Visual Science 1991;32:1925-1931.
22. Kador PF, Betts D, Wyman M et al. Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose. American Journal of Veterinary Research 2006; 67: 1783-1787.
23. Kinoshita JH, Kador P, Datiles M. Aldose reductase in diabetic cataracts. JAMA 1981; 246: 257-261.
24. Mulhern ML, Madson CJ, Kador PF et al. Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Molecular Vision 2007; 13: 1397-1405.